Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has worked conscientiously but unsuccessfully to produce a single therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination treatment in the curing of multi-drug-resistant HIV happen to be closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale of the last few shares of mine. The first CytoDyn post of mine, “CytoDyn: What to be able to Do When It’s Too Good To Be True?”, set out all of the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely marketing picture in the Uptick Newswire job interview which I came away with an inadequate impression of the business.

Irony of irony, my bad opinion of the business enterprise has grown steadily, yet the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the treatment and prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity of HIV infected subjects. Today’s transaction of $3.5 million transfers ownership of the expertise as well as associated intellectual property from Progenics to CytoDyn, and also approximately 25 million mg of majority drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 zillion) plus the very first new drug application endorsement ($5 million), and also royalty payments of 5 % of net sales upon commercialization.

Since that time, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and many therapies, it’s this single treatment in addition to a “broad pipeline of indications” since it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a likely beneficial therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an energetic business with diverse interests albeit centered on leronlimab, several illness sorts, multiple delivering presentations in addition to multiple publications.

Could all of it be smoke cigarettes and mirrors? That’s a question I’ve been asking myself from the really beginning of my interest in this particular company. Judging with the multiples of a huge number of various responses on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m far from alone in this question.

CytoDyn is a classic battleground, or possibly some could say cult stock. Its adherents are fiercely shielding of its prospects, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *